Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2018
 
Surgery Partners, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-37576
47-3620923
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
310 Seven Springs Way, Suite 500
Brentwood, Tennessee 37027
(Address of Principal Executive Offices) (Zip Code)
 
(615) 234-5900
(Registrant's Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. o
 





Item 2.02 Results of Operations and Financial Condition.
On November 7, 2018, Surgery Partners, Inc. issued a press release announcing results for the three and nine months ended September 30, 2018. See the press release attached as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.
Surgery Partners makes reference to non-GAAP financial information in the attached press release and a reconciliation of GAAP to non-GAAP results is provided therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release dated November 7, 2018.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
SURGERY PARTNERS, INC.
 
 
By:
/s/ Thomas F. Cowhey
Thomas F. Cowhey
Executive Vice President and Chief Financial Officer
Date: November 7, 2018





EXHIBIT INDEX
Exhibit
Number
 
Description
 
 
 
99.1
 




Exhibit
Exhibit 99.1

http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12534833&doc=3
SURGERY PARTNERS, INC. ANNOUNCES THIRD QUARTER 2018 RESULTS
Near Term Results Reflect Ongoing Traction of Strategic Growth Initiatives; Continued Investments to Drive Accelerated Growth in 2019

BRENTWOOD, Tenn., November 7, 2018 (GLOBE NEWSWIRE) - Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the third quarter ended September 30, 2018.
Revenues increased 44.9% to $443.9 million
Same store revenues increased 11.4% over prior period
Surgical cases increased 13.9% to 127,199
Net loss attributable to common stockholders of $29.2 million
Adjusted EBITDA increased 153.8% to $59.0 million
Diluted net loss per share of $(0.61)
Adjusts full year 2018 Adjusted EBITDA guidance to $230 million - $235 million
Wayne DeVeydt, Chief Executive Officer of Surgery Partners, stated, “Our third quarter results were highlighted by strong year over year revenue and surgical case growth, as well as same store volume growth, a trend which has carried over into October. We continue to advance our agenda both operationally and strategically, as we remain focused on pruning the portfolio, investing in our platforms and processes and deploying capital to continue to execute on our inorganic growth opportunities.”
Mr. DeVeydt continued, “Looking ahead to 2019, we firmly believe that the investments we have made in 2018 will drive organic growth across our business and leave us well positioned to make real progress towards our goal of becoming the trusted partner of choice for operating short stay surgical facilities across the United States.”
Tom Cowhey, Chief Financial Officer of Surgery Partners, commented, “Third quarter results demonstrated good progress as we reposition the company for growth in 2019. However, when we considered the seasonal increases that were required to hit our previous projection, coupled with our pruning efforts and continued growth investments, we made a decision to lower our 2018 Adjusted EBITDA projection to a range of $230 to $235 million.”
Third Quarter 2018 Results
Total revenues for the third quarter of 2018 increased 44.9% to $443.9 million from $306.3 million for the third quarter of 2017. Same-facility revenues for the third quarter of 2018 increased 11.4% from the same period last year, with a 10.5% increase in revenue per case and a 0.9% increase in same facility cases. For the third quarter of 2018, the Company’s net loss attributable to common stockholders was $29.2 million compared to $31.8 million for the same period last year. For the third quarter of 2018, the Company’s Adjusted EBITDA increased 153.8% to $59.0 million compared to $23.2 million for the same period last year.
Year to Date 2018 Results
Total revenues year to date 2018 increased 48.3% to $1,306.1 million from $880.9 million for the same period last year. Same-facility revenues year to date 2018 increased 4.6% from the same period last year, with a 6.2% increase in revenue per case offset by a 1.5% decrease in same facility cases. For year to date 2018, the Company’s net loss attributable to common stockholders was $81.9 million compared to $39.0 million for the same period last year. For year to date 2018, the Company’s Adjusted EBITDA increased 60.8% to $161.5 million compared to $100.4 million for the same period last year.

1


Liquidity
Surgery Partners had cash and cash equivalents of $79.1 million at September 30, 2018 and availability of approximately $60.5 million under its revolving credit facility. Net operating cash inflow, including operating cash flow less distributions to non-controlling interests, was $5.1 million for the third quarter of 2018. The Company’s ratio of total net debt to EBITDA, as calculated under the Company’s credit agreement was 7.75x at the end of the third quarter of 2018.
Guidance
The Company is revising its full-year 2018 guidance to revenue in the range of $1.75 to $1.80 billion and Adjusted EBITDA in the range of $230 million to $235 million. The Company now expects to deploy at least $100 million in capital for acquisitions in FY’18.
Conference Call Information
Surgery Partners will hold a conference call today, November 7, 2018 at 8:30 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-855-327-6837, or for international callers, 1-631-891-4304. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 10005798. The replay will be available until November 21, 2018.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at www.surgerypartners.com. The on-line replay will remain available for a limited time beginning immediately following the call.
To learn more about Surgery Partners, please visit the company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution for material Company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 32 states, including ambulatory surgery centers, surgical hospitals, a diagnostic laboratory, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding growth and our anticipated operating results for 2018 and other similar statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects,” “forecasts,” and similar expressions. All forward looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those discussed in, or implied by, the forward-looking statements, including but not limited to, the risks identified and discussed from time to time in the Company’s reports filed with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.
Use of Non-GAAP Financial Measures
In addition to the results prepared in accordance with generally accepted accounting principles in the United States ("GAAP") provided throughout this press release, Surgery Partners has presented the following non-GAAP financial measures: EBITDA, Adjusted EBITDA and adjusted net (loss) income, which exclude various items detailed in the attached "Reconciliation of Non-GAAP Financial Measures".
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not

2


presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from those used by other companies. These measures have limitations as an analytical tool, and should not be considered in isolation or as a substitute or alternative to net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
In connection with the Preferred Private Placement and the Private Sale, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission on September 1, 2017, the Company elected to apply “pushdown” accounting with the change of control effective August 31, 2017, by applying the guidance in Accounting Standards Codification Topic ("ASC") 805, Business Combinations. Accordingly, the consolidated financial statements of the Company for periods before and after August 31, 2017 will reflect different bases of accounting, and the financial positions and results of operations of those periods are not comparable. Throughout the Company's condensed consolidated financial statements and the accompanying notes therein to be filed no later than November 9, 2018, periods prior to the change of control are identified as "Predecessor" and periods after the change of control are identified as "Successor."


3


SURGERY PARTNERS, INC.
SELECTED CONSOLIDATED FINANCIAL DATA
(Amounts in thousands, except shares and per share amounts)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Revenues
 
$
443,932

 
$
306,337

 
$
1,306,076

 
$
880,873

Operating expenses:
 
 
 
 
 
 
 
 
Salaries and benefits
 
131,441

 
103,024

 
395,196

 
282,933

Supplies
 
120,123

 
83,106

 
355,701

 
228,350

Professional and medical fees
 
34,902

 
25,483

 
107,294

 
69,185

Lease expense
 
21,629

 
16,061

 
64,910

 
43,361

Other operating expenses
 
26,194

 
19,022

 
78,590

 
51,267

Cost of revenues
 
334,289

 
246,696

 
1,001,691

 
675,096

General and administrative expenses
 
19,478

 
20,378

 
69,729

 
54,574

Depreciation and amortization
 
16,945

 
10,929

 
49,379

 
33,454

Provision for doubtful accounts
 
11,555

 
8,524

 
25,788

 
19,987

Income from equity investments
 
(1,861
)
 
(1,608
)
 
(6,283
)
 
(3,860
)
Loss on disposals and deconsolidations, net
 
12,631

 
447

 
15,875

 
2,048

Transaction and integration costs
 
7,099

 
5,326

 
23,771

 
8,567

Loss on debt refinancing
 

 
18,211

 

 
18,211

Gain on litigation settlement
 

 

 

 
(3,794
)
Gain on acquisition escrow release
 

 
(1,000
)
 

 
(1,000
)
Other (income) expense
 
(1,207
)
 
4

 
(3,601
)
 
(300
)
Total operating expenses
 
398,929

 
307,907

 
1,176,349

 
802,983

Operating income (loss)
 
45,003

 
(1,570
)
 
129,727

 
77,890

Gain on amendment to tax receivable agreement
 

 
16,392

 

 
16,392

Interest expense, net
 
(37,159
)
 
(34,030
)
 
(107,368
)
 
(84,812
)
Income (loss) before income taxes
 
7,844

 
(19,208
)
 
22,359

 
9,470

Income tax expense (benefit)
 
5,825

 
(20,929
)
 
10,905

 
(18,300
)
Net income
 
2,019

 
1,721

 
11,454

 
27,770

Less: Net income attributable to non-controlling interests
 
(23,000
)
 
(15,305
)
 
(69,418
)
 
(48,579
)
Net loss attributable to Surgery Partners, Inc.
 
(20,981
)
 
(13,584
)
 
(57,964
)
 
(20,809
)
Less: Amounts attributable to participating securities (1)
 
(8,245
)
 
(18,199
)
 
(23,973
)
 
(18,199
)
Net loss attributable to common stockholders
 
$
(29,226
)
 
$
(31,783
)
 
$
(81,937
)
 
$
(39,008
)
 
 
 
 
 
 
 
 
 
Net loss per share attributable to common stockholders
 
 
 
 
 
 
 
 
Basic
 
$
(0.61
)
 
$
(0.66
)
 
$
(1.71
)
 
$
(0.81
)
Diluted (2)
 
$
(0.61
)
 
$
(0.66
)
 
$
(1.71
)
 
$
(0.81
)
Weighted average common shares outstanding
 
 
 
 
 
 
 
 
Basic
 
48,037,634

 
48,203,265

 
48,020,369

 
48,143,359

Diluted (2)
 
48,037,634

 
48,203,265

 
48,020,369

 
48,143,359


(1) Includes dividends accrued during the three and nine months ended September 30, 2018 and 2017 for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.
(2) The impact of potentially dilutive securities for all periods presented was not considered because the effect would be anti-dilutive in those periods.

4



SURGERY PARTNERS, INC.
Selected Financial and Operating Data
(Amounts in thousands, except shares and per share amounts)
 
 
September 30,
2018
 
December 31,
2017
 
 
 
 
 
Balance Sheet Data (at period end):
 
 
 
 
Cash and cash equivalents
 
$
79,123

 
$
174,914

Total current assets
 
463,318

 
563,225

Total assets
 
4,558,664

 
4,622,773

 
 
 
 
 
Current maturities of long-term debt
 
54,106

 
58,726

Total current liabilities
 
295,586

 
303,005

Long-term debt, less current maturities
 
2,118,567

 
2,130,556

Total liabilities
 
2,661,464

 
2,656,041

 
 
 
 
 
Non-controlling interests—redeemable
 
317,541

 
299,316

Redeemable preferred stock
 
350,893

 
330,806

 
 
 
 
 
Total Surgery Partners, Inc. stockholders' equity
 
571,072

 
654,731

Non-controlling interests—non-redeemable
 
657,694

 
681,879

Total stockholders' equity
 
1,228,766

 
1,336,610

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Cash Flow Data:
 
 
 
 
 
 
 
 
Net cash provided by (used in):
 
 
 
 
 
 
 
 
Operating activities
 
$
29,414

 
$
10,025

 
$
99,054

 
$
66,496

Investing activities
 
(11,788
)
 
(718,364
)
 
(66,611
)
 
(747,559
)
Capital expenditures
 
(10,674
)
 
(5,511
)
 
(26,618
)
 
(20,613
)
Payments for acquisitions, net of cash acquired
 
(7,319
)
 
(712,853
)
 
(55,213
)
 
(727,016
)
Financing activities
 
(34,572
)
 
851,006

 
(128,234
)
 
811,065

Distributions to non-controlling interests
 
(24,315
)
 
(19,946
)
 
(80,091
)
 
(56,787
)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Other Data:
 
 
 
 
 
 
 
 
Number of surgical facilities as of the end of period
 
124

 
124

 
124

 
124

Number of consolidated surgical facilities as of the end of period
 
105

 
109

 
105

 
109

 
 
 
 
 
 
 
 
 
Cases
 
127,199

 
111,674

 
383,713

 
332,261

Revenue per case
 
$
3,490

 
$
2,743

 
$
3,404

 
$
2,651

Adjusted EBITDA
 
$
58,988

 
$
23,244

 
$
161,465

 
$
100,406

Adjusted EBITDA as a % of revenues
 
13.3
%
 
7.6
%
 
12.4
%
 
11.4
%
Adjusted EPS- Basic
 
$
(0.19
)
 
$
(0.39
)
 
$
(0.63
)
 
$
(0.37
)
Adjusted EPS- Diluted
 
$
(0.19
)
 
$
(0.39
)
 
$
(0.63
)
 
$
(0.37
)

5




SURGERY PARTNERS, INC.
Supplemental Information
(Amounts in thousands, except cases and growth rates)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,

 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Same-facility Information:
 
 
 
 
 
 
 
 
Cases (3)
 
136,919

 
135,742

 
412,599

 
418,919

Case growth
 
0.9
%
 
N/A

 
(1.5
)%
 
N/A

Revenue per case (3)
 
$
3,460

 
$
3,132

 
$
3,376

 
$
3,178

Revenue per case growth
 
10.5
%
 
N/A

 
6.2
 %
 
N/A


(3) Same-facility revenues include revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods) along with the revenues from our ancillary services comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services and optical services that complement our surgical facilities in our existing markets.

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Segment Revenues:
 
 
 
 
 
 
 
 
Surgical facility services
 
$
420,514

 
$
293,360

 
$
1,234,984

 
$
814,320

Ancillary services
 
20,719

 
10,184

 
62,655

 
58,036

Optical services
 
2,699

 
2,793

 
8,437

 
8,517

Total revenues
 
$
443,932

 
$
306,337

 
$
1,306,076

 
$
880,873


 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Adjusted EBITDA:
 
 
 
 
 
 
 
 
Surgical facility services
 
$
74,525

 
$
48,673

 
$
216,540

 
$
146,859

Ancillary services
 
875

 
(12,002
)
 
2,925

 
(7,791
)
Optical services
 
571

 
748

 
2,087

 
2,407

All other
 
(16,983
)
 
(14,175
)
 
(60,087
)
 
(41,069
)
Total adjusted EBITDA
 
$
58,988

 
$
23,244

 
$
161,465

 
$
100,406



6


SURGERY PARTNERS, INC.
Reconciliation of Non-GAAP Financial Measures
(Amounts in thousands)

The following table reconciles Adjusted EBITDA to income before income taxes in the reported condensed consolidated financial information, the most directly comparable U.S. GAAP financial measure:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
Condensed Consolidated Statements of Operations Data (4):
 
 
 
 
 
 
 
 
Income before income taxes
 
$
7,844

 
$
(19,208
)
 
$
22,359

 
$
9,470

Minus:
 
 
 
 
 
 
 
 
Net income attributable to non-controlling interests
 
23,000

 
15,305

 
69,418

 
48,579

Plus:
 
 
 
 
 
 
 
 
Interest expense, net
 
37,159

 
34,030

 
107,368

 
84,812

Depreciation and amortization
 
16,945

 
10,929

 
49,379

 
33,454

EBITDA
 
38,948

 
10,446

 
109,688

 
79,157

Plus (minus):
 
 
 
 
 
 
 
 
Equity-based compensation expense
 
1,526

 
3,311

 
6,303

 
5,380

Transaction, integration and acquisition costs (5)
 
7,489

 
6,406

 
25,419

 
11,134

Reserve adjustments (6)
 
(2,109
)
 

 
2,670

 

Loss on disposals and deconsolidations, net
 
12,631

 
447

 
15,875

 
2,048

Contingent acquisition compensation expense
 
503

 
1,815

 
1,510

 
5,662

Gain on litigation settlement
 

 

 

 
(3,794
)
Gain on acquisition escrow release
 

 
(1,000
)
 

 
(1,000
)
Gain on amendment to tax receivable agreement
 

 
(16,392
)
 

 
(16,392
)
Loss on debt refinancing
 

 
18,211

 

 
18,211

Adjusted EBITDA
 
$
58,988

 
$
23,244

 
$
161,465

 
$
100,406


(4) The above table reconciles Adjusted EBITDA to income before income taxes as reflected in the unaudited condensed consolidated statements of operations.
When we use the term “Adjusted EBITDA,” it is referring to income before income taxes adjusted for: (a) net income attributable to non-controlling interests, (b) depreciation and amortization, (c) interest expense, net, (d) equity-based compensation expense, (e) contingent acquisition compensation expense, (f) transaction, integration and acquisition costs, (g) reserve adjustments, (h) loss on disposals and deconsolidations, net, (i) gain on litigation settlement, (j) gain on acquisition escrow release, (k) gain on amendment to tax receivable agreement and (l) loss on debt refinancing. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that we consolidate for financial reporting purposes. We believe that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors our portion of Adjusted EBITDA generated by our surgical facilities and other operations.
Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating our financial performance. We believes such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.
(5) This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended September 30, 2018 and 2017, respectively, and acquisition costs of $0.4 million and $1.1 million for the three months ended September 30, 2018 and 2017, respectively. This amount includes transaction and integration costs of $23.8 million and $8.6 million for the nine months ended September 30, 2018 and 2017, respectively, and acquisition costs of $1.6 million and $2.6 million for the nine months ended September 30, 2018 and 2017, respectively.
(6) This amount represents adjustments to revenue in connection with applying consistent policies across the combined company as a result of the integration of Surgery Partners and NSH.
    


7


SURGERY PARTNERS, INC.
Reconciliation of Non-GAAP Financial Measures
(Amounts in thousands, except shares and per share amounts)

From time to time, the Company incurs certain non-recurring gains or losses that are normally nonoperational in nature and that it does not consider relevant in assessing its ongoing operating performance. When significant, Surgery Partners’ management and Board of Directors typically exclude these gains or losses when evaluating the Company’s operating performance and in certain instances when evaluating performance for incentive compensation purposes. Additionally, the Company believes that certain investors and equity analysts exclude these or similar items when evaluating the Company’s current or future operating performance and in making informed investment decisions regarding the Company. Accordingly, the Company provides adjusted net (loss) income per share attributable to common stockholders as a supplement to its comparable GAAP measure of net (loss) income per share attributable to common stockholders. Adjusted net (loss) income per share attributable to common stockholders should not be considered a measure of financial performance under GAAP, and the items excluded from adjusted net (loss) income per share attributable to common stockholders are significant components in understanding and assessing financial performance. Adjusted net (loss) income per share attributable to common stockholders should not be considered in isolation or as an alternative to net income per share attributable to common stockholders as presented in the consolidated financial statements.
The following table reconciles net income as reflected in the consolidated statements of operations to adjusted net (loss) income used to calculate adjusted net (loss) income per share attributable to common stockholders:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Consolidated Statements of Operations Data:
 
 
 
 
 
 
 
 
Net Income
 
$
2,019

 
$
1,721

 
$
11,454

 
$
27,770

Minus:
 
 
 
 
 
 
 
 
Net income attributable to non-controlling interests
 
23,000

 
15,305

 
69,418

 
48,579

Amounts attributable to participating securities (7)
 
8,245

 
18,199

 
23,973

 
18,199

Plus (minus):
 
 
 
 
 
 
 
 
Equity-based compensation expense
 
1,526

 
3,311

 
6,303

 
5,380

Transaction, integration and acquisition costs
 
7,489

 
6,406

 
25,419

 
11,134

Reserve adjustments
 
(2,109
)
 

 
2,670

 

Loss on disposals and deconsolidations, net
 
12,631

 
447

 
15,875

 
2,048

Contingent acquisition compensation expense
 
503

 
1,815

 
1,510

 
5,662

Gain on litigation settlement
 

 

 

 
(3,794
)
Gain on amendment to tax receivable agreement
 

 
(16,392
)
 

 
(16,392
)
Gain on acquisition escrow release

 

 
(1,000
)
 

 
(1,000
)
Loss on debt refinancing
 

 
18,211

 

 
18,211

Adjusted net loss attributable to common stockholders
 
$
(9,186
)
 
$
(18,985
)
 
$
(30,160
)
 
$
(17,759
)
 
 
 
 
 
 
 
 
 
Adjusted net loss per share attributable to common stockholders
 
 
 
 
 
 
 
 
Basic
 
$
(0.19
)
 
$
(0.39
)
 
$
(0.63
)
 
$
(0.37
)
Diluted (8)
 
$
(0.19
)
 
$
(0.39
)
 
$
(0.63
)
 
$
(0.37
)
Weighted average common shares outstanding
 
 
 
 
 
 
 
 
Basic
 
48,037,634

 
48,203,265

 
48,020,369

 
48,143,359

Diluted (8)
 
48,037,634

 
48,203,265

 
48,020,369

 
48,143,359


(7) Includes dividends accrued during the three and nine months ended September 30, 2018 and 2017 for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.
(8) The impact of potentially dilutive securities for the three and nine months ended September 30, 2018 and 2017, was not considered because the effect would be anti-dilutive in each of those periods.



8


Contact
 
Thomas F. Cowhey, Chief Financial Officer
Surgery Partners, Inc.
(615) 234-8940
IR@surgerypartners.com

9